Officials announced the launch of a new biotechnology company called OSPRI in August, which will be headquartered in McKinney.

The biotechnology company specializes in polymerase chain reaction-based infectious disease technology, otherwise known as PCR tests. OSPRI enables healthcare clinics and laboratories to manage infectious disease testing in-house while accelerating results and improving clinical outcomes, according to a news release.

OSPRI was formed by a merger between three Texas-based companies: Community Direct DX, Scienetix and the R&D division of Advanta Genetics. It’s led by Dr. Rahul Sharma, Dr. Sadia Almas and Dr. Alaina Vincent.

The merger is financed by up to $30 million from healthcare investment firm Catalio Capital Management. Headquartered in McKinney, OSPRI serves clients across 20 states and multiple clinical specialties.

“OSPRI exists to solve the real problems of cost and complexity in infectious disease testing,” Vincent said in a statement. “Innovation should be accessible—not exclusive. Our goal is to enable better, faster care for more patients by equipping providers with the tools they need to lead.”


In the next one to two years, OSPRI officials plan to expand its R&D team by 40% while growing commercial operations by 25% to meet increased demand, according to the news release.

“Our production capabilities have grown exponentially,” said Jeremy Adamic, a partner at OSPRI. “We now deliver over 40,000 tests per day with multilayered quality control—scaling both volume and reliability.”